Elanco Animal Health Inc: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 8, 2024 and accepted by EDGAR at May 8, 2024, 09:06 ET.
Management's discussion and analysis
As filed, 27,040 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Introduction
Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Form 10-Q. Certain statements in this Item 2 of Part I of this Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in “Forward-Looking Statements” of this Form 10-Q, in Item 1A, “Risk Factors” of Part II of this Form 10-Q and in Item 1A, “Risk Factors” of Part I of our 2023 Form 10-K, may cause our actual results, financial position and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.
Business Overview
Elanco is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. Our diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health) and cattle, poultry, swine, sheep and aqua (collectively, farm animal). With a heritage dating back to 1954, we consistently innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment, directed at advancing the well-being of animals, people and the planet, enabling us to realize our vision of Food and Companionship Enriching Life.
Our diverse product portfolio of approximately 200 brands helps make us a trusted partner to pet owners, veterinarians and farm animal producers. Our products are generally sold worldwide to third-party distributors and independent retailers, and directly to farm animal producers and veterinarians. In recent years, we have expanded our omnichannel presence in both the veterinary clinic and in retail markets, including e-commerce.
Product Development and Regulatory Update
A key element of our targeted value creation strategy is to drive revenue growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules, as well as additional registrations and indications for current products. Our future growth and success depend on both our pipeline of new products, including new products we develop internally, develop with partners or that we obtain through licenses or acquisitions, and the life cycle management of our existing products. We believe we are an industry leader in animal health R&D, with a track record of successful product innovation, business development and commercialization.
Other Key Trends and Factors Affecting Our Results of Operations
Acquisition and Integration Activity: In 2023 we acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest) and certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil). Additionally, in April 2023 we successfully completed the integration of the Bayer Animal Health business into our enterprise resource planning (ERP) system. We incurred costs totaling $93 million in 2023 related to integration activities, including the build out of processes and systems to support our global organization. In connection with this integration, we notified our customers of an expected commercial blackout period during specified periods of time in April 2023, during which certain products would not be able to be shipped. Due to this, we believe certain customers modified their purchasing habits, causing a shift of revenue from the second quarter of 2023 to the first quarter of 2023 of approximately $90 million to $110 million, based on our high-level estimates. While first quarter 2023 revenue benefited from this shift in purchases, this resulted in a corresponding decrease in revenue during the second quarter of 2023.
Aqua Business Divestiture: On February 5, 2024, we entered into an agreement to sell our aqua business to a subsidiary of Merck Animal Health for approximately $1.3 billion in cash, payable at closing, which we currently anticipate to occur around mid-year 2024. Our aqua business includes products across both warm-water and cold-water species and generated $31 million and $40 million in revenue during the three months ended March 31, 2024 and 2023, respectively. Upon closing of this sale, we intend to use the after-tax cash proceeds to accelerate debt repayment and reduce our leverage and future interest expense. Strategically, this divestiture allows us to prioritize our investments in larger markets with greater long-term earnings potential. The closing of the transaction is subject to customary conditions, including the receipt of applicable antitrust approvals. If the agreement is terminated due to failure to obtain required antitrust approvals, subject to certain conditions, Merck Animal Health will be required to pay us a termination fee of $55 million in cash. Based on our current estimates, we expect to recognize a pre-tax gain on sale in the range of $600 million to $650 million. Income tax expense associated with this sale is expected to be in the range of $170 million to $190 million. See Note 4. Acquisitions, Divestitures and Other Arrangements to the condensed consolidated financial statements for further information.
Restructuring Activities: In February 2024, our Board of Directors authorized a restructuring plan (the restructuring plan) to improve operational efficiencies and better align our organizational structure with current business needs, top strategic priorities and key growth opportunities. Specifically, the restructuring plan was intended to reallocate resources by shifting international resources from farm animal to pet health as we plan for the global launches of certain blockbuster potential products currently under regulatory review. Further, the restructuring plan has impacted how we operate in and sell into the Argentina market, among others, reducing our foreign currency exposure in those markets.
Total expected pre-tax charges associated with the restructuring plan total $50 to $55 million in 2024, of which $39 million was incurred during the first quarter of 2024, the majority relating to cash-based severance costs. The restructuring plan is expected to result in the elimination of approximately 420 personnel across our global organization and annualized net savings of $30 to $35 million. See Note 5. Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements for further information.
Macroeconomic Factors: As a global company with products sold in more than 90 countries, our operations are exposed to and are impacted by various global macroeconomic factors. We face continuing market and operating challenges across the globe due to, among other factors, the Russia-Ukraine conflict, conditions related to supply chain disruption, higher interest rates, foreign currency exchange rate volatility and inflationary pressures. Continued evolution of these conditions has led to economic slowdowns in certain countries and/or regions and volatility in consumer behavior. We anticipate global macroeconomic pressures to continue throughout 2024.
Seasonality: While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. For example, based upon historical results, approximately 75% and 60% of total annual revenue contributed by our higher-margin parasiticide products Seresto and Advantage Family, respectively, typically occurs during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere.
Results of Operations
The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto. Our results of operations for the periods presented below may not be comparable with prior periods or with our results of operations in the future due to many factors, including but not limited to the factors identified above.
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Revenue | $1,205 | $1,257 | (4)% |
| Costs, expenses and other: | |||
| Cost of sales | 515 | 494 | 4% |
| % of revenue | 43% | 39% | |
| Research and development | 87 | 81 | 7% |
| % of revenue | 7% | 6% | |
| Marketing, selling and administrative | 337 | 327 | 3% |
| % of revenue | 28% | 26% | |
| Amortization of intangible assets | 133 | 134 | (1)% |
| Asset impairment, restructuring and other special charges | 46 | 40 | 15% |
| Interest expense, net of capitalized interest | 66 | 64 | 3% |
| Other expense, net | 9 | 9 | —% |
| Income before income taxes | 12 | 108 | (89)% |
| Income tax (benefit) expense | (20) | 5 | NM |
| Net income | $32 | $103 | (69)% |
Certain amounts and percentages may reflect rounding adjustments.
NM – Not meaningful
Revenue
As a global company, our products are sold in more than 90 countries, and as a result, a significant portion of our revenue is recorded in currencies other than the U.S. Dollar. Because of this, our revenue is influenced by changes in foreign currency exchange rates. During the three months ended March 31, 2024 and 2023, approximately 52% and 53% of our revenue was denominated in foreign currencies, respectively.
Further, increases or decreases in inventory levels in our distribution channels can positively or negatively impact our quarterly revenue results, leading to variations in revenue. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our control. For example, in connection with the integration of the Bayer Animal Health business into our ERP system, we communicated commercial shipping blackout periods that occurred in April 2023. Given this timing, we believe certain customers modified purchasing habits, which we estimate caused a shift of revenue from the second quarter of 2023 to the first quarter of 2023 of approximately $90 million to $110 million. While first quarter 2023 revenue benefited from this shift in purchases, this resulted in a corresponding decrease in revenue during the second quarter of 2023. This estimated shift of quarterly revenue in the prior year is a principal contributor to the year-over-year volume declines experienced during the three months ended March 31, 2024.
On a global basis, our revenue by product category for the three months ended March 31, 2024 and 2023, was as follows:
(Dollars in millions)
| Revenue 2024 | 2023 | % of Total Revenue 2024 | 2023 | Increase (Decrease) $ Change | % Change | CC (1) | |
|---|---|---|---|---|---|---|---|
| Pet Health | $639 | $675 | 53% | 54% | $(36) | (5)% | (5)% |
| Farm Animal | 556 | 573 | 46% | 46% | (17) | (3)% | (3)% |
| Contract Manufacturing (2) | 10 | 9 | 1% | 1% | 1 | 11% | 12% |
| Total | $1,205 | $1,257 | 100% | 100% | $(52) | (4)% | (4)% |
Note: Numbers may not add due to rounding
(1) Constant Currency (CC), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange rates. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.
(2) Represents revenue from arrangements in which we manufacture products on behalf of a third-party.
On a global basis, the effects of price, foreign currency exchange rates and volume on changes in revenue for the three months ended March 31, 2024, compared to the three months ended March 31, 2023, were as follows:
(Dollars in millions)
| Revenue | Price | FX Rate | Volume | Total | CC | |
|---|---|---|---|---|---|---|
| Pet Health | $639 | 3% | —% | (8)% | (5)% | (5)% |
| Farm Animal | 556 | —% | —% | (3)% | (3)% | (3)% |
| Contract Manufacturing | 10 | (2)% | (1)% | 14% | 11% | 12% |
| Total | $1,205 | 2% | —% | (6)% | (4)% | (4)% |
Note: Numbers may not add due to rounding
Pet health revenue decreased $36 million, or 5%, for the three months ended March 31, 2024, compared to the same period in 2023, driven by lower volumes and partially offset by a 3% increase in pricing. The primary driver of the lower volumes was the impact of the ERP system integration commercial blackout periods in the prior year, which we believe shifted an estimated $65 million to $80 million in pet health revenue from the second quarter of 2023 to the first quarter of 2023. This impact to volumes, in addition to the slow start to the U.S. parasiticide season and continued competitive pressure on certain products in the U.S. veterinary channel, were partially offset by increased vaccine sales due to easing of supply constraints, improved demand for retail parasiticide products in certain European markets, including Spain, and the impact of an initial stocking of certain legacy Bayer Animal Health products into the U.S. distribution channel.
Farm animal revenue decreased $17 million, or 3%, for the three months ended March 31, 2024, compared to the same period in 2023. The primary driver of the lower volumes was the impact of the ERP system integration commercial blackout periods in the prior year, which we believe shifted an estimated $25 million to $30 million of revenue from the second quarter of 2023 to the first quarter of 2023. This impact to volumes, as well as market weakness impacting the swine business in China, was partially offset by increased revenue from new products, led by Experior, and strength in poultry sales globally.
Cost of Sales
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Cost of sales | $515 | $494 | 4% |
| % of revenue | 43% | 39% |
Cost of sales increased $21 million for the three months ended March 31, 2024, and cost of sales as a percentage of revenue increased from 39% for the three months ended March 31, 2023, to 43% for the three months ended March 31, 2024. These increases were due to a combination of inflation, the impact of product mix, which was driven by the impact of the ERP system integration commercial blackout periods on higher margin products in the prior year, and planned reduced throughput at certain manufacturing sites in support of efforts to reduce inventory balances and improve cash conversion.
Research and Development
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Research and development | $87 | $81 | 7% |
| % of revenue | 7% | 6% |
Research and development expenses increased $6 million for the three months ended March 31, 2024, as compared to the same period in the prior year, primarily driven by higher employee-related expenses and timing of project costs.
Marketing, Selling and Administrative
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Marketing, selling and administrative | $337 | $327 | 3% |
| % of revenue | 28% | 26% |
Marketing, selling and administrative expenses increased $10 million for the three months ended March 31, 2024, as compared to the same period in the prior year, primarily driven by increases in marketing and promotional spend supporting our global pet health business and higher employee-related expenses. These increases were partially offset by cost savings associated with the completion of our ERP system integration in the second quarter of 2023.
Amortization of Intangible Assets
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Amortization of intangible assets | $133 | $134 | (1)% |
Amortization of intangible assets decreased $1 million for the three months ended March 31, 2024, as compared to the same period in the prior year. Partially contributing to this decrease, as of February 1, 2024, the date we concluded the assets to be sold as part of our aqua business divestiture qualified as held for sale, we ceased the amortization of the finite-lived intangible assets included within this disposal group. See Note 4. Acquisitions, Divestitures and Other Arrangements to the condensed consolidated financial statements for further information.
Asset Impairment, Restructuring and Other Special Charges
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Asset impairment, restructuring and other special charges | $46 | $40 | 15% |
Asset impairment, restructuring and other special charges increased $6 million for the three months ended March 31, 2024, as compared to the same period in the prior year. Amounts recorded during the three months ended March 31, 2024, consist of $39 million of costs associated with the restructuring plan announced in February 2024 and $7 million of acquisition integration and divestiture-related costs. Amounts recorded during the three months ended March 31, 2023, primarily represented costs associated with the implementation of new systems, programs, and processes due to the integration of Bayer Animal Health. For additional information regarding our asset impairment, restructuring and other special charges, see Note 5. Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.
Interest Expense, Net of Capitalized Interest
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Interest expense, net of capitalized interest | $66 | $64 | 3% |
Interest expense, net of capitalized interest increased $2 million for the three months ended March 31, 2024, as compared to the same period in the prior year, primarily due to higher weighted-average interest rates.
Other Expense, Net
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Other expense, net | $9 | $9 | —% |
Other expense, net for the three months ended March 31, 2024 and 2023, primarily consisted of foreign exchange losses. During the three months ended March 31, 2024, we also increased our accrual for the possible resolution or settlement with the SEC by $2.5 million, which was included within other expense, net.
Income Tax (Benefit) Expense
(Dollars in millions)
| Three Months Ended March 31, 2024 | 2023 | % Change | |
|---|---|---|---|
| Income tax (benefit) expense | $(20) | $5 | NM |
| Effective tax rate | (182.2)% | 4.4% |
We recognized an income tax benefit of $20 million for the three months ended March 31, 2024, compared to income tax expense of $5 million for the same period in the prior year. The income tax benefit during the three months ended March 31, 2024, was primarily driven by the partial release of a valuation allowance attributable to the anticipated sale of our aqua business and a benefit related to the recognition of certain state tax credits.
Liquidity and Capital Resources
Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, the income taxes associated with transferring cash to the U.S. We intend to indefinitely reinvest substantially all foreign earnings for continued use in our foreign operations. As our business evolves, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.
We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations, such as principal and interest payments, as well as interest rate swaps, operating lease payments, purchase obligations and costs associated with mergers, acquisitions, divestitures and business integrations and/or restructuring activities. As of March 31, 2024, we had cash and cash equivalents of $345 million and unused borrowing capacity on our Revolving Credit Facility of approximately $550 million. In addition, our Securitization Facility provides additional borrowing capacity in the event our borrowing capacity on this facility, which is correlated to our U.S. Net Eligible Receivables Balances, exceeds our outstanding borrowings on the facility. As of March 31, 2024, we had undrawn borrowing capacity of $114 million on our Securitization Facility. We also have the ability to access capital markets to obtain debt financing for longer-term funding, if required. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.
Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As market conditions change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We have substantial indebtedness" in Part I of our 2023 Form 10-K.
Cash Flows
The following table provides a summary of cash flows from operating, investing and financing activities for the three months ended March 31, 2024 and 2023:
(Dollars in millions)
| Net cash provided by (used for): | 2024 | 2023 | $ Change |
|---|---|---|---|
| Operating activities | $2 | $(145) | $147 |
| Investing activities | 37 | (55) | 92 |
| Financing activities | (27) | 174 | (201) |
| Effect of exchange-rate changes on cash and cash equivalents | (19) | (1) | (18) |
| Net decrease in cash and cash equivalents | $(7) | $(27) | $20 |
Operating activities
Cash provided by operating activities was $2 million for the three months ended March 31, 2024, compared to cash used for operating activities of $145 million for the three months ended March 31, 2023. The change in cash provided by (used for) operating activities was driven by a year-over-year improvement in changes in operating assets and liabilities, partially offset by lower net income.
Investing activities
Cash provided by investing activities was $37 million for the three months ended March 31, 2024, compared to cash used for investing activities of $55 million for the three months ended March 31, 2023. Cash provided by investing activities during the three months ended March 31, 2024, was driven by the collection of a $66 million receivable related to our previous divestiture of our Shawnee and Speke locations (see Note 4. Acquisitions, Divestitures and Other Arrangements to the condensed consolidated financial statements for additional information). These proceeds were partially offset by net purchases of property and equipment and software and a deferred cash payment related to our prior year acquisition of NutriQuest. Cash used for investing activities during the three months ended March 31, 2023, primarily related to net purchases of property and equipment and software, $16 million paid for the acquisition of NutriQuest and $14 million for the purchase of intangible assets.
Financing activities
Cash used for financing activities was $27 million for the three months ended March 31, 2024, compared to cash provided by financing activities of $174 million for the three months ended March 31, 2023. Cash used for financing activities during the three months ended March 31, 2024, included $13 million in scheduled repayments of long-term borrowings. Cash provided by financing activities of $174 million during the three months ended March 31, 2023, primarily reflected proceeds from our revolving credit facility, partially offset by the repayment of indebtedness outstanding under our long-term borrowings.
Description of Indebtedness
For a complete description of our existing debt and available credit facilities as of March 31, 2024 and December 31, 2023, see Note 8. Debt within Item 8, “Financial Statements and Supplementary Data,” of Part II of our 2023 Form 10-K. New developments are discussed in Note 8. Debt of this Form 10-Q.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our 2023 Form 10-K. There were no significant changes or developments in the application of our critical accounting policies during the three months ended March 31, 2024.
Market risk
As filed, 2,401 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Foreign Exchange Risk
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. We are exposed to foreign currency exchange risk as the functional currency financial statements of non-U.S. subsidiaries are translated to U.S. dollars. We are also subject to foreign currency transaction gains and losses to the extent revenue and expense transactions are not denominated in the functional currency of a subsidiary. We are primarily exposed to foreign currency exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.
Additionally, we generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. We have applied hyperinflationary accounting for our Argentina and Turkey subsidiaries since 2018 and 2022, respectively, and as a result, have changed their functional currencies to the U.S. dollar. During the three months ended March 31, 2024, revenue in Argentina and Turkey each represented less than 1% of our consolidated revenue, and assets held in Argentina and Turkey as of March 31, 2024, each represented less than 1% of our consolidated assets. Further, in February 2024 our Board of Directors authorized a restructuring plan that, among other strategic decisions, has resulted in a change in how we operate in and sell into the Argentina market, which has reduced our foreign currency exposure with respect to the Argentine peso. In spite of this, and while the application of hyperinflationary accounting for our subsidiaries in Argentina and Turkey did not have a material impact on our business during the three months ended March 31, 2024, we may in the future incur further currency devaluations, which could have a material adverse impact on our results of operations.
Interest Risk
At March 31, 2024, we held interest rate swap agreements with a notional value of $3,800 million that had the economic effect of modifying this amount of our variable-rate debt to fixed-rate. When including variable-rate converted to fixed-rate through the use of interest rate swaps, as of March 31, 2024, approximately 78% of our long-term indebtedness bore interest at a fixed rate.
Controls and procedures
As filed, 1,142 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized and reported on a timely basis.
Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of March 31, 2024, and concluded they were effective.
(b) Changes in Internal Controls. During the first quarter of 2024, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 177 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our risk factors are documented in Item 1A of Part I of our 2023 Form 10-K. There have been no material changes from the risk factors previously disclosed in the 2023 Form 10-K.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $1.21bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-01-01 to 2024-03-31 | $515.0m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2024-01-01 to 2024-03-31 | $87.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-01-01 to 2024-03-31 | $337.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2024-01-01 to 2024-03-31 | $66.0m | us-gaap:InterestExpense |
| Income tax | 3 months2024-01-01 to 2024-03-31 | −$20.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | $32.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | $0.06 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 496,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | $2.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2024-01-01 to 2024-03-31 | $24.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-03-31 | $345.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $4.05bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $14.02bn | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $1.23bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $7.96bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-03-31 | $5.73bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-03-31 | $38.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-03-31 | $6.06bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739104-24-000018. Last ingested by Listed: Nov 13, 2026, 16:18 ET. Listed shows no prices and gives no investment advice.